Customer Outcomes & Value Experiencing A New Monitoring Technology
NCT ID: NCT04262700
Last Updated: 2020-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
170 participants
INTERVENTIONAL
2020-02-07
2020-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Blood Glucose Monitoring Devices With New Insight Features
NCT02929654
Clinical Evaluation of LifeScan Blood Glucose Monitoring Systems
NCT03920085
Clinical Benefits of a Blood Glucose Monitoring System in Patients With Type 2 Diabetes
NCT00401622
Blood Glucose Monitoring System Clinical Study
NCT01327209
Comparison Study of Blood Glucose Monitoring Systems in People With Diabetes
NCT01234727
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention 01
Subjects use new LifeScan provided BGMS for 12 weeks.
LifeScan's new BGMS
LifeScan new Blood Glucose Monitoring System (BGMS)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LifeScan's new BGMS
LifeScan new Blood Glucose Monitoring System (BGMS)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Currently performing self-monitoring of blood glucose (SMBG) at home for diabetes management decisions
* Willingness to notify the study staff if they become pregnant during the study
* Willing to sign an informed consent
Exclusion Criteria
* Currently pregnant or planning pregnancy within duration of study or breast feeding; subjects who become pregnant during the study will be withdrawn.
* Conflict of Interest
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LifeScan Scotland Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Infirmary of Edinburgh
Edinburgh, Lothian, United Kingdom
Highland Diabetes Institute
Inverness, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Alison Sudworth
Role: primary
David MacFarlane, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FILE-PROT-005120
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.